Literature DB >> 12101279

Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.

Andreas Ludwig1, Florian Schiemann, Rolf Mentlein, Buko Lindner, Ernst Brandt.   

Abstract

Dipeptidyl peptidase IV (DPP IV/CD26) is a costimulatory molecule as well as a protease highly expressed on T cells. Purified DPP IV has been recognized to inactivate peptide hormones, neuropeptides, and some chemokines by cleavage behind a proline residue at the penultimate N-terminal amino acid position. Here, we identified another substrate for DPP IV among the chemokine family: the interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11). Using a specific DPP IV inhibitor, we demonstrate that DPP IV is responsible for the cleavage of the chemokine by PHA/IL-2-treated T cells. As PHA/IL-2-treated T cells also express the CXCL11 receptor (CXCR3), we investigated whether truncation of CXCL11 would modulate its biological activity for these cells. Truncated CXCL11 [CXCL11(3-73)] had an eightfold reduced potential to bind and to regulate CXCR3, but was completely inactive in calcium flux and chemotaxis assays. However, consistent with its reduced but still considerable ability to down-regulate CXCR3, truncated CXCL11 desensitized T cell chemotaxis in response to the intact chemokine. Hence, CXCL11-induced T cell recruitment may be regulated by DPP IV-mediated proteolytic inactivation of CXCL11 and furthermore by desensitization of T cells via the degradation product CXCL11(3-73).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101279

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  28 in total

1.  Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines.

Authors:  Urska Repnik; Amanda E Starr; Christopher M Overall; Boris Turk
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157

2.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

Authors:  Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

4.  Interleukin-29: Just an extra string in the bow of Th17 cells or a target for therapeutic exploitation?

Authors:  Andrew Johnston
Journal:  J Mol Med (Berl)       Date:  2016-04       Impact factor: 4.599

5.  Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration.

Authors:  David Vergote; Georgina S Butler; Martine Ooms; Jennifer H Cox; Claudia Silva; Morley D Hollenberg; Jack H Jhamandas; Christopher M Overall; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

6.  Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.

Authors:  H-J Mest; R Mentlein
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

7.  Discrimination of agonist and antagonist forms of CXCL10 in biological samples.

Authors:  A Casrouge; A Bisiaux; L Stephen; M Schmolz; J Mapes; C Pfister; S Pol; V Mallet; M L Albert
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 8.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

9.  Induced-fit mechanism for prolyl endopeptidase.

Authors:  Min Li; Changqing Chen; David R Davies; Thang K Chiu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).

Authors:  Valerie Booth; Ian Clark-Lewis; Brian D Sykes
Journal:  Protein Sci       Date:  2004-08       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.